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ABSTRACT 
To evaluate ocular surface changes after withdrawal of Benzalkonium chloride (BAK) in patients with glaucoma in 
monotherapy with BAK-preserved prostaglandin. This was a prospective observational study. All patients underwent 
complete ophthalmologic examination and evaluation of ocular surface. A questionnaire was filled regarding symptoms 
of dry eye (Ocular Surface Disease Index [OSDI]) at the beginning of study. The treatment was switched to preservative-
free tafluprost for 6 weeks and after this period, all patients were re-evaluated. All patients reported improvement of 
symptoms. The green lissamine test showed a significant improvement of the ocular surface, with most patients 
classified as light dry eye (P < 0.001). A significant improvement in the score (P < 0.001) was also found, with an average 
of 17.95 ± 5.35 points, which classifies the patients' symptoms in the normal to light zone. Benzalkonium chloride 
withdrawal reduced the signs and symptoms of dry eye in patients with primary open angle glaucoma (POAG). 
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INTRODUCTION
Glaucoma is a chronic disease and the second leading 
cause of irreversible blindness in the world [1]. The main 
risk factor is intraocular pressure (IOP) and currently, the 
only treatable one. One of the first treatment options is 
drug therapy to reduce IOP, since the control of this 
factor delays the progression of glaucoma and 
consequently blindness. In the last decade, availability of 
prostaglandin analogous eye drops has facilitated the 
management of patients with glaucoma. They are 
currently the first drug of choice in the treatment of 
glaucoma due to potent IOP reduction, few adverse 
reactions, only daily application and good adherence. 
Although prostaglandin analogs are safe eye drops, they 
are known to have side effects related both to the 
specific properties of each analog, as well as to the 
preservatives used in these medications [2]. The well-
known characteristic side effects of prostaglandins (PG) 
include iris pigmentation, eyelid pigmentation, eyelash 
extension and deepening of the upper eyelid sulcus [3]. 
Side effects commonly occur with PG-related drugs and 
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other ophthalmic antiglaucomatous agents include 
ocular surface diseases (OSDs) such as tear reduction and 
superficial punctate keratopathy (SPK). In addition, to the 
ophthalmic antiglaucomatous agent itself, the effects of 
preservatives have been indicated as a causative factor 
of OSD associated with ophthalmic antiglaucomatous 
agent administration. [4] Preservatives are used to inhibit 
the growth of microorganisms in eye drops bottles, 
making safe the use of multi-drop vials. They also protect 
biodegradation and help maintain drug potency. 
Benzalkonium chloride (BAK) one of the most commonly 
used preservatives in antiglaucomatous medications, is a 
cationic surfactant that binds to the cell membranes of 
microorganisms, increasing permeability and 
consequently cell lysis. Previous studies have shown that 
BAK has a toxic effect on the ocular surface, as it has a 
detergent effect on the lacrimal layer of the tear film. 
Also, it has pro-inflammatory properties and induces 
apoptosis of goblet cells [5-7]. 
There are many studies indicating that more than 60% of 
patients with glaucoma have signs and symptoms of 
ocular surface disease (OSD). Therefore, the purpose of 
this study was to evaluate ocular surface changes after 
withdrawal of BAK in patients with glaucoma who use 
eyedrops of prostaglandin analogs preserved with BAK 
[8]. 
METHOD 
This prospective observational study adhered to the 
tenants of the Declaration of Helsinki and was approved 
by the Institutional Review Board. Additionally, a written 
informed consent was obtained from all participants. We 
enrolled patients with primary open angle glaucoma. The 
definition of glaucoma was based on the presence of 
repeatable (≥ 2 consecutive) abnormal standard 
automatic perimetry (SAP) test results on the 24-2 
program of the VF (Humphrey Field Analyzer; Carl Zeiss 
Meditec, Inc.) or if progressive glaucomatous optic disc 
changes were noted on stereo photographs, regardless 
of the results of SAP. We have described abnormal SAP 
results as those with a pattern standard deviation index 
outside the 95% confidence limits and/or glaucoma 
hemifield test results outside the reference range. The 
inclusion criteria were age > 18 years, treatment for 
glaucoma with monotherapy prostaglandin for at least 6 
months and symptoms of dry eyes. The exclusion criteria 
were Sjogren’s syndrome, Steven’s Johnson syndrome, 
ocular surgery in the last year including refractive 
surgery, allergy to some component of eye drops, 
pregnancy, systemic diseases affecting the ocular surface 
or any systemic medication affecting the ocular surface. 
All patients underwent complete ophthalmologic 
examination at the beginning of the study (visual acuity 
without and with correction, biomicroscopy, eyelid 
examination, conjunctiva, cornea and tear film), 
complete anamnesis where the complaints were 
recorded. However, a questionnaire of ocular surface 
disease was filled for each patient to evaluate the impact 
of ocular surface changes on daily activities. The 
diagnostic tests used in this study were Schirmer's test, 
Green lissamine test, tear film break-up time (BUT) and 
Goldmann applanation tonometry. Tear film BUT was 
measured following the guidelines described in the Dry 
Eye Workshop (DEWS) report[9]. Staining of the cornea 
with lissamine green was performed and graded 
according to the Bijsterveld’s scale [10]. Schirmer I test 
without anesthesia was performed following the 
guidelines published in the DEWS report [11]. Schirmer 
paper strips were inserted in the eye over the lower lid 
margin, midway between the middle and the outer third. 
The patient was asked to close the eye, and after 5 
minutes, the wetting of the Schirmer paper was 
measured. Intraocular pressure measured with a slit 
lamp–mounted Goldmann applanation tonometer. Dry 
eye symptoms were assessed using the Ocular Surface 
Disease Index (OSDI). The questionnaire underlying the 
OSDI is specifically designed for patients with dry eye 
syndrome and asks patients regarding the frequency of 
specific symptoms and their impact on vision-related 
functioning. After the exams, patients received sufficient 
free samples of tafluprosta (Saflutan) eye drops for the 
use of a drop once overnight for 6 weeks. Such samples 
were provided by the examiner to avoid discontinuation 
of treatment for socioeconomic reasons. 
After 6 weeks, all patients underwent a new evaluation 
with the same exams and questionnaire. In this work, the 
diagnosis of dry eye was established as tear film BUT less 
than 5 seconds, Schirmer test less than 5 mm and / or 
Green lissamine test greater than 3 according to the van 
Bijsterveld scale (0 to 9) [9] (Fig 1). 
Descriptive statistics were calculated for demographic 
and clinical characteristics. The means and standard 
deviations (SD) presented for the normally distributed 
variables and medians and interquartile ranges 
presented for non-normally distributed variables. Paired 
t-test was used to compare differences in the scores 
before and after the medication change. All statistical 
analyses were performed with Stata computer software 
(version 13; StataCorp LP, College Station, Texas, USA). 
The alpha level was set at 0.05. 
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RESULT 
Eleven patients (22 eyes) were evaluated, 8 women and 
3 men. All patients had the diagnosis of primary open-
angle glaucoma and used BAK preserved prostaglandin 
analog eye drops as monotherapy for at least one year. 
The mean age was 64.9 ± 6.07 years. In this sample, 6 
patients used bimatoprost 0.3%, 2 Travoprost 0.004% 
and 3 latanoprost 0.005%. At the beginning of the study, 
all patients had a dry eye diagnosis with at least 2 
diagnostic exams with altered results and had an 
important complaint of foreign body sensation and 
burning eyes. The Schirmer test had a mean score of 
5.0.9 ± 2.75 mm (range 1-10 mm); The tear film BUT 
presented an average of 6.68 ± 2.07 seconds (range 3-10 
seconds); The green lissamine test was a moderate to 
severe dry eye in 15 eyes with a Bijsterveld index with a 
mean of 6.27 ± 2.72 (range 1-6). Intraocular pressure 
showed an average of 11.5 ± 1.56 mmHg (range 9 - 
14mmHg). All patients answered 10 questions of the 
OSDI questionnaire, since 2 questions did not apply to 
any patient in the study. The average score obtained in 
the analysis of the questionnaire was 35.27 ± 10.67 
points (range 17.5 - 60 points), characterizing the 
patients' symptoms in mild to moderate. 
 
 
Figure 1: Van Bijsterveld‘s Scale
After 6 weeks, all patients were re-examined. All 
reported improvement of symptoms and only 4 patients 
complained of a slight sensation of sand in the eyes. The 
Schirmer test presented a mean ± SD of 4.36 ± 2.40 mm 
(range 1-12 mm) without significant improvement (P = 
0.198); tear film BUT score had a mean ± SD of 5.5 ± 2.15 
seconds (range 3-10 seconds) without significant 
improvement (P = 0.113); the green Lissamine test 
showed a significant improvement of the ocular surface, 
with most patients classified as light dry eye (P < 0.001). 
The Bijsterveld index presented a mean ± SD of 3.04 ± 
1.25 (range 1-5). A significant improvement in the score 
(P < 0.001) was also found, with a mean ± SD of 17.95 ± 
5.35 points (range 5-25 points), which classifies the 
patients' symptoms in the normal to light zone. 
 
 
DISCUSSION 
This study demonstrated a significant improvement in 
OSDI and in van Bijsterveld’s scale in patients who were 
using PG with BAK replaced by PG without BAK. This is 
the first study to evaluate ocular surface using OSDI and 
clinical evaluation in patients using PG with and without 
BAK.  
Currently, the only accepted way for preserving visual 
function in patients with glaucoma is reducing IOP. 
Although the disease is multifactorial, IOP remains the 
only modifiable risk factor for prevention or delay of 
visual deterioration. Chronic use of hypotensive eyedrops 
is associated with several adverse effects such as 
allergies, conjunctivitis, contact dermatitis, punctate 
keratitis and even failure of filtering surgery. This toxicity 
appears to be more associated with the preservative BAK 
than with the active component of the medication. From 
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this point of view, single-dose preservative-free 
preparations would be a viable alternative to the 
currently used multiple-dose drops of eyedrops [12, 13]. 
This study demonstrated a significant improvement in 
OSDI questionnaire score and in lissamine green score in 
patients who were using PG with BAK replaced by PG 
without BAK. The decrease in ocular surface staining and 
reduction in the symptoms as observed in our study is in 
accordance with previous studies, which demonstrated 
that BAK is one of the major triggers that induces OSD in 
patients with long-term glaucoma therapy [1, 8, 9, 14] 
and the adverse effects are reversible, as we found 
replacing preserved to preservative free topical anti-
glaucoma therapy. 
Furthermore, we found a considerable improvement in 
self-reported quality of life of patients with glaucoma in 
accordance with previous studies that analyze symptoms 
and signs with preserved and preservative-free glaucoma 
medications in general [7, 15, 16]. Although, most studies 
use a washout period in this study, patients had straight 
substituted treatment from preserved to unpreserved 
prostaglandins, resembling daily clinical practice. 
Replacement of eyedrops without washout had no 
impact on IOP-lowering efficacy in patients, which were 
well controlled before study in accordance with previous 
studies [3, 7, 14]. 
In patients with glaucoma, tear dysfunction is mainly 
attributed to chronic administration of preserved 
glaucoma medications. Benzalkonium chloride is known 
to damage the ocular surface, reduce the density of 
epithelial and goblet cells and alter the lipid layer. These 
changes result in an impaired tear film with excessive 
evaporation [17]. There are different findings in 
symptoms and signs of dry eye between glaucoma-
treated patients and controls in many studies. Van Went 
et al. [18] found that only tear film BUT and fluorescein 
staining grade were significantly altered in patients with 
treated glaucoma compared to untreated control group, 
and there was no significant difference for Schirmer test 
and OSDI. Some studies [16, 19] also reported 
significantly reduced tear film BUT and Schirmer test.  
Uusitalo et al. [20] showed a significant increase in tear 
film BUT after the substitution from preserved 
latanoprost to preservative-free tafluprost suggesting  
that tear film stability is increased after withdrawal of 
preservative, but not observed in this study. This finding 
might be explained by the factors that influence the 
reproducibility of these tests, like natural fluctuations 
during the day, different populations, variations in 
measurement techniques and scoring, systemic 
medications, environmental differences [21] or it could 
be also consequence of the small sample size and the 
absence of other tests to evaluate the tear film like 
osmolality and tear film thickness. 
A significant improvement was seen in the OSDI as a 
reduction in complaints about symptoms related to 
ocular surface. This result associated with a decrease in 
ocular surface staining, and consequently improvement 
of keratitis, as observed in our study may suggest that 
avoiding BAK exposure improves the health of the ocular 
surface.  
This study had some limitations; the sample size was 
limited to 22 eyes. However, this is one of the first 
studies comparing two medications with and without 
BAK, therefore, these preliminary results confirm the 
effect of BAK in ocular surface of patients with glaucoma. 
Second, there was no randomization without mask and 
data collection was performed by only one examiner, 
which allows patient or observer bias, mainly at the 
assessment of OSDI symptoms. Besides, this was a cross-
sectional study. Longitudinal studies have to be 
performed to evaluate the BAK effect during a certain 
period. Lastly, the effect of ocular surface in quality of life 
of patients with glaucoma was not assessed. Further 
studies would be necessary to measure the real impact 
of BAK effect in these patients. As glaucoma requires a 
continuous treatment, it is important to assure the 
adherence to the treatment. Nevertheless, some signs 
and symptoms of ocular surface disease, like conjunctival 
hyperemia, foreign body sensation or irritation difficult 
this adherence [22]. Once it could be avoided or get 
better, probably the overall glaucoma management and 
outcomes will improve. 
CONCLUSION 
We found similar results to those found in the literature, 
which makes it possible to suggest that change of 
prostaglandin analogs BAK-preserved to tafluprost 
preservative-free is possible and can bring some benefits 
for patients like improvement of self-reported symptoms 
and reduction of clinical signs of dry eye in patients with 
glaucoma maintaining effective IOP control. 
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